



in collaboration with



SARS-CoV-2


WHAT TO KNOW AND HOW TO MOVE FORWARD

THE VIRUS & DISEASE
ENVIRONMENTAL SAFETY
STAFF WELL-BEING
MONITORING AND TESTING

Dr Massimo Cristaldi

Coronavirus size 120 nM


$$1\text{nM} = 1 \times 10^{-9}$$



Manuel Bortoletti

- Made of 4 proteins and a strand of RNA (molecule which can store genetic information)
- One protein is the spike, which gives the crown-like appearance
 - Two proteins sit in the membrane between the spikes to provide structural integrity
 - In the membrane, the fourth protein is a scaffold around the genetic material

COMPARATIVE SCALE




Enters through **nose, mouth, or eyes**. Attaches to cells in the respiratory tract producing a protein called ACE2

- It fuses with the cell and releases the RNA; the hijacked infected cell will produce proteins based on the “instructions” from the virus’ RNA
- Each infected cell can release millions of copies of the virus before dying
- Affects **upper respiratory tract**, can **spread to lungs**
- In serious cases, immune system can overreact and attack lung cells; in some cases, the infection leads to acute respiratory distress syndrome and possibly death
- The virus can also end up in droplets that escape the lungs through **coughing/sneezing/ breathing** - micro droplets but also possible airborne in certain condition - surface contamination

COVID-19 is more infectious than influenza.

Reproduction¹ and fatality² for selected human viruses




¹As determined at the beginning of an outbreak; can be reduced by effective intervention.

²Case-fatality numbers are reflective of the outbreak setting and depend on a number of factors, including patient's age, community immunity, health-system capabilities, etc. This graphic aims to offer a broad comparison.

Source: Expert interviews; World Health Organization; McKinsey analysis

R0 number of person infected by each infected individuals


R0=3after 10 rounds = **62000 infected individuals**



DEATH rate/age

Data from three countries show that older populations are at greater risk.

Case-fatality rate by age segment,¹ % mortality



¹As of data from Feb 11, 2020, in China and as of March 16 and 15, 2020, in South Korea and Italy, respectively.

²Data reported from China Feb 11, 2020, reports 2.3%, however latest deaths/cases from WHO indicate this may be higher.

Source: China CDC; Korea CDC; L'Istituto Superiore di Sanità (ISS) Italy; WHO; McKinsey analysis

SARS-CoV-2



PUBLIC HEALTH MEASURES

CONTAINMENT

Identify infected - Isolate - Treat - Trace contacts and repeat

Why It doesn't quite work that way in SARS-CoV-2?

Up to 70% of individuals may be asymptomatic/minimal symptoms

- **Identify** infected - Isolate - Treat - Trace contacts and repeat



TESTING is CRUCIAL

3T's

PUBLIC HEALTH MEASURES

MITIGATION

- Social distancing
- Movement restriction
- Lock down
- Adequate/increase healthcare response


SARS-CoV-2: THE “PERFECT WEAPON”

- Wide spectrum of disease
- “Stealth” transmission
- Infected are difficult to identify
- Long incubation and super-efficient transmissibility
- Very contagious - Mildly infective
- Very lethal in severe forms

SARS-CoV-2 TESTING

- Molecular Test RT-PCR
Complex - Long - High % of false negative - Early
- Antigen Test
Easy - Rapid - Higher % of false negative - Early
- Serology Test
Easy - Rapid - Higher level of accuracy - Late

SARS-CoV-2—SPECIFIC SEROCONVERSION




IgG Sero-conversion is 100% within 19 days

SEROLOGY TESTING


- Serology Surveys
3-60% immunes
- Seroconversion = Immunity?
- Does high AB levels (titre) matter?
- How long does the immunity last after infection?

WHERE ARE WE NOW?

- Epidemics are Invisible threats
Human psychology plays crucial role
- 3 Phases
Denial/Blaming/Over-reaction
- Currently different stages of the curve
Some have Flatten the curve/ 2nd wave
- Psychological adapted and  readiness

WHERE ARE WE NOW?

COVID-19 Cases by Country



> 32 millions/over 30 year

SARS-CoV-2 is 5 months-old-baby

- A lot will be discovered in the next few months
- Acute cases treatment will be fine tuned but...
- There is **no real prospect of definitive cure**
- Most effective **cure** is **vaccination**
- Can we expect a **vaccine soon?**

VACCINE **72 DIFFERENT ONGOING PROJECTS**

- Real prospect as we have for similar viruses
- Developing it goes through very routinized phases
- **Development**
- **Phase 1** - Safety - Tens - Weeks
- **Phase 2** - Immunogenicity/Safety - Tens/Hundreds - Months
- **Phase 3** - Efficacy - Thousands - Year(s) Challenge studies?

STRATEGY FOR BUSINESS

Pillars

- **PPEM - Personal Protective Equipment/Safety Measures**
- **Environmental Safety**
- **Individual behaviors in/off work**
- **Testing strategies**
- **Monitoring**

PPEM - Personal Protective Equipment/Measures

- Daily prescreening before entering premises
Temperature (IR-scanners) - Symptoms / Database
- Face Masks
Surgical masks - How and When
- Hand Hygiene
Proper washing - Hand sanitizer available on desks
- Surface decontamination
How and When
- Avoidance of cross-exchanging tools/document

Face Masks

Laser Light-Scattering Experiment Showing Speech-Generated Droplets.

Without mask

Pause



00:01 / 00:41

Speech-generated droplets and their trajectories are shown while the speaker was unmasked and masked.

“HERD PROTECTION”

ENVIRONMENTAL SAFETY

- Avoid over-crowding
No close contacts/meeting or gathering
- Environment hygiene
Air circulation - Humidifier and Air Purifiers
- Implement and use video conference systems
Webex meeting/Team - Microsoft Team
- No common canteen or coffee rooms - unless properly spaced
- Ad hoc and segregated staff accommodations
- Outdoor work policies/education (realistic policies)



INDIVIDUAL BEHAVIORS

- Education

Face mask / Hygiene / Personal interactions

- Team leaders

Reinforcement / Monitoring

- Off work circumstances

Single / Family / Kids at school ect

- Self discipline

Education / Responsibility / Reinforcement

TESTING STRATEGIES

- After social distancing and isolation
Serology Surveys - PCR mass testing
- Individual at higher risk of complication or exposed to +ve
PCR testing
- Interval serology surveys
Immunity based License/Passport
- Risk Management - Isolate individuals at higher risks

DEFINITION OF CLOSE CONTACTS


Exposure to individuals PCR +ve or with COVID related symptoms

- Time >15'
- Proximity <2 meters
- Face masks No - poor usage
- Individual circumstances Co-morbidities

MONITORING

- Management of outbreaks
- Temporary closures of premises
- Contact tracing (3T)
- Interval Sero-surveys - 4/6 wks
- Management and support of +ve
- Periodical sanification of working places

TECHNOLOGY



SafeTag by KINEXION

+ve Cases

- Medical Management
- Provide a Roadmap
- Psychological support
- Family management
- Testing close contacts

Resuming work after COVID

- No symptoms and 2 serial -ve PCR tests
 - 7 days after first +ve PCR if No/Minimal symptoms
 - 14 days after +ve PCR in symptomatic patients
- Medical Fitness only after moderate/severe infection
 - Interval chest x-rays/examination/Spirometry
- Serology testing
 - Qualitative and Quantitative

TRAVEL POLICY

- Reduce staff traveling unless necessary
- Define pre-condition for traveling
- Implement local Government policy
Immunity Passport
- Set your own policy and safety standards

SYNERGISTIC MEASURES

- Each measure adopted in isolation is going to **FAIL**
- Strong education and reinforcement
- Invest in education, safety and well-being of workforce
- Financial support during quarantine/work absence
- Moral and practical support for +ve - remove stigma

Education

Evidence-based Reassurance

Engagement

Self-Discipline

Discipline

RESILIENCE

FINAL OUTCOME

We will all get infected or
Vaccinated*

** first come, first served*